Speakers

Expand/Collapse

Andrea Crotti
Principal Scientist
Astellas

Day One

4:00 pm | The Role of Microglial BIN1 in Alzheimer’s Disease: From Genetics to Target Validation

Anindya Bhattacharya
Scientific Director
Janssen

Day Two

4:15 pm | Discovery to Clinical Evaluation of Neuroinflammation: The Microglial P2X7-NLRP3 Axis

Christian Haass
Professor, Laboratory of Neurodegenerative Disease
University of Munich

Day Two

10:45 am | TREM2, from Basic Functions to a Therapeutic Target

David Hansen
Scientist
Genentech

Day One

8:45 am | Microglia: Suppress or Promote?

Dimitry Ofengeim
Neuroinflammation-Lab Head
Sanofi

Day One

8:15 am | The Interface of Inflammation & Cell Death: Disease Progression in Multiple Sclerosis & Beyond

Eduard Urich
Principle Scientist
Roche

Jamie Bilsland
Chief Scientific Officer
AstronauTx

Day One

2:30 pm | Moving Away from Microglial Targets & Appreciating Astrocyte Contribution

Jane Osbourn
Chief Scientific Officer
Alchemab

Day Two

2:45 pm | Panel Discussion: Investing in Neuroinflammatory Targets & Backing Smaller Companies Research

Johan Luthman
Executive Vice President, Research & Development
Lundbeck

Day One

11:30 am | From Animal to Man: Building Target Engagement to Proof of Concept Pathway

Jonathan Behr
Partner
Dementia Discovery Fund

Day Two

2:45 pm | Panel Discussion: Investing in Neuroinflammatory Targets & Backing Smaller Companies Research

Karel Otero-Gutierrez
Principal Scientist
Eisai

Day Two

9:15 am | Audience Discussion: Working with the Right Cells In Vitro

Karpagam Shalu Srinivasan
Senior Scientist
Alector

Day One

12:00 pm | Stabbing in the Dark: Biomarkers of Microglial Pathway Activation

Kate Monroe
Associate Director and Senior Scientist
Denali Therapeutics

Day Two

11:15 am | Mechanisms of Targeting TREM2 with a Dual Function Antibody

Maciej Kaliszczak
Senior Scientist, RED Biomarker
Biogen

Day One

3:00 pm | Exploring Nuclear Imaging Approaches to Understand & Monitor Neuroinflammation

Malu Tansey
Director, Center for Translational Research in Neurodegenerative Disease & the Parkinson’s Foundation Research Center
The University of Florida College of Medicine

Day One

4:30 pm | Panel Discussion: Are We Chasing the Wrong Phenomenon?

Day Two

11:45 am | The Role of Innate Immune Dysfunction & Chronic Inflammatory Disease in Neurodegeneration

Maria Carrillo
Chief Science Officer
Alzheimer’s Association

Day Two

1:45 pm | Beyond the Usual Suspects: Promoting Novel Thinking

Matt Blurton-Jones
Associate Professor, Department of Neurobiology & Behavior
University of California, Irvine

Day Two

8:15 am | Using iPS-Microglia & Chimeric Models to Examine the Neuroimmunology of Alzheimer's Disease

Matthew Fell
Principal Scientist, Neuroimmunology
Merck Research Laboratories

Day One

12:30 pm | The Challenge of Developing Translatable Biomarkers to Guide the Clinical Interrogation of LRRK2 Kinase Inhibitors for Parkinson’s Disease

Matthew Havrda
Assistant Professor
The Geisel School of Medicine at Dartmouth

Michael Mingueneau
Associate Director, Multiple Sclerosis & NeuroInflammation Research
Biogen

Michael Mingueneau is an immunologist experienced with target identification, validation and advancing drug discovery programs in the fields of Immunology, Neuroimmunology and Autoimmunity. As R&D project lead at Biogen, he directs a group of scientists on a cross-functional project team to progress and develop a small molecule kinase inhibitor that is positioned as a candidate treatment for both relapsing and progressive forms of Multiple Sclerosis. Michael Mingueneau is also spearheading the MS research unit strategy aiming at developing transformative Next-Generation immunomodulators that will effectively target CNS-compartmentalized inflammation, a pathological process which has been linked to cortical demyelination and clinical disease progression in MS patients. Before joining the MS research unit, Michael was part of the Biogen Immunology department and led target identification and validation efforts in peripheral autoimmune indications including Sjögren’s disease, SLE and scleroderma. Before Biogen, Michael Mingueneau completed his postdoctoral training in the laboratories of Drs. C. Benoist and D. Mathis (Harvard Medical School, Boston, US) following Ph.D. studies with Dr. B. Malissen (CIML, Marseille, France). He previously developed genetically engineered mouse models and used systems biology approaches to better understand cellular differentiation of immune cells in both physiological (Immgen project, www.immgen.org) and pathological conditions (type-1 diabetes, lymphoproliferative disorders). One common focus of interest in his prior and current research activities relates to the mechanisms by which immune cells decode, transform and integrate information, and make cellular decisions in steady-state and disease. Leveraging this knowledge for target identification/validation and advancing drug discovery programs in the fields of Immunology, Neuroimmunology and Autoimmunity has been one of his main goals as a drug discovery scientist.

Day Two

12:15 pm | SAM Microglia, a Novel Storage-Body Accumulating Subset in Steady- State & Aging

Nicole Polinski
Senior Associate Director, Research Programs
The Michael J Fox Foundation

Day Two

2:15 pm | The Michael J. Fox Foundation’s Efforts to Improve Understanding of Inflammation in Parkinson’s Disease

Rebecca Mathew
Senior Scientist, GpGx-Genome Sciences
Merck Research Laboratories

Day One

2:00 pm | Single Cell Sequencing & Spatial Transcriptomic Approaches to Characterize Human Cells & Tissues

Richard Ransohoff
Venture Partner
Third Rock Ventures

Day One

4:30 pm | Panel Discussion: Are We Chasing the Wrong Phenomenon?

RJ Tesi
Chief Executive Officer & Chief Medical Officer
INmune Bio

Day Two

5:15 pm | Panel Discussion: Optimizing Clinical Trial Study Design & Finding the Appropriate Controls for Patients

3:15 pm | Recipe for Success: Design Neuro Trials to Look Like Oncology Trials!

Robert Paul
Chief Medical Officer
Alector

Day Two

5:15 pm | Panel Discussion: Optimizing Clinical Trial Study Design & Finding the Appropriate Controls for Patients

4:45 pm | Reviewing Early Biomarker Read Outs to Improve Drug Development

Sue Bruhn
Chief Executive Officer & President
Tiaki Therapeutics

Day Two

8:45 am | Development of Targets Identified from Patients & Validated With Ex Vivo & In Vivo Models of Neuroinflammation